Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 701–800 of 1,000
Novel treatment regimens for Waldenström’s macroglobulinemia
García‐Sánz, R., & Ocio, E. M. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.19 · Cited by 16
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes
Bonkowski, J. J., Vermeulen, L. C., & Kolesar, J. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209351967 · Cited by 16
The risk of secondary primary malignancies after therapy for multiple myeloma
Areethamsirikul, N., & Reece, D. E. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.974043 · Cited by 16
Activation of coagulation by a thalidomide-based regimen
Hoshi, A., Matsumoto, A., Chung, J., Isozumi, Y., & Koyama, T. (2011) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328348629d · Cited by 18
Bone marrow vascular niche and the control of angiogenesis in multiple myeloma
Ribatti, D., Basile, A., Ruggieri, S., & Vacca, A. (2014) · Frontiers in bioscience · doi:10.2741/4209 · Cited by 17
Plasma cell maturity as a predictor of prognosis in multiple myeloma
Iriyama, N., Miura, K., Hatta, Y., Uchino, Y., Kurita, D., Takahashi, H., Sakagami, H., Sakagami, M., Kobayashi, Y., Nakagawa, M., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0803-3 · Cited by 16
“The recent development of novel agents, including bortezomib and lenalidomide, has led to dramatic improvements in the outcomes of patients with multiple myeloma (MM) [1–3].”
BackgroundNew monoclonal antibodies on the horizon in multiple myeloma
O’Donnell, E., & Raje, N. S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716682490 · Cited by 16
Şahin, U., & Demirer, T. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21591 · Cited by 18
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16
“The clinical outcome of patients with multiple myeloma has been improved in recent decades due to the development of novel therapeutic agents such as the proteasome inhibitors bortezomib [3], carfilzomib [4,5], and ixazomib [6] or immunomodulatory drugs (IMiDs) including thalidomide [7], lenalidomide [8], and pomalido…”
BackgroundCerebrospinal fluid penetrance of lenalidomide in meningeal myeloma
Anwer, S., Collings, F., Trace, K., Sun, Y., & Sternberg, A. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12351 · Cited by 16
Novel drugs for the treatment of multiple myeloma
Bladé, J., Cibeira, M. T., & Rosiñol, L. (2010) · Haematologica · doi:10.3324/haematol.2009.021550 · Cited by 16
Jeong, J., Levine, M. S., Abayasekara, N., Berliner, N., Laubach, J. P., & Vanasse, G. J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0136-2 · Cited by 15
“Chemotherapy regimens incorporating the use of bortezomib [3,5] or lenalidomide [21] are increasingly becoming standard of care in the treatment of patients with relapsed multiple myeloma.”
BackgroundGeorge, L. L., Malik, M. N., Miller, E. J., Hicks, K., Khanam, R., Saterehaseman, A., McNichol, M. C., & Anwer, F. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.013 · Cited by 15
Park, I., Phan, T. M., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13205084 · Cited by 15
Messori, A., Maratea, D., Nozzoli, C., & Bosi, A. (2011) · PharmacoEconomics · doi:10.2165/11585930-000000000-00000 · Cited by 15
Treatment of multiple myeloma bone disease: experimental and clinical data
Papamerkouriou, Y. M., Kenanidis, E. I., Gamie, Z., Papavasiliou, K., Kostakos, T. A., Potoupnis, M. E., Sarris, I. K., Tsiridis, E. E., & Kyrkos, J. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.978853 · Cited by 16
Safety and efficacy of primary thromboprophylaxis in cancer patients
Escobar, I. G., Rebollo, M. T. A., Adrián, S. G., Garzotto, A. A. R., & Martín, A. J. M. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1500-6 · Cited by 15
Armoiry, X., Connock, M. J., Tsertsvadze, A., Cummins, E., Meléndez‐Torres, G. J., Royle, P., & Clarke, A. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0644-3 · Cited by 15
“Takeda and NICE suggested Dimopoulos et al., 2014 as an external data source; in this publication PFS and OS were reported for LEN-DEX patients pooled from two RCTs (MM-010 and MM-009) [9, 10].”
BackgroundInfluentialCamilli, M., Vecchia, G. L., Lillo, R., Iannaccone, G., Lamendola, P., Montone, R. A., Hohaus, S., Aspromonte, N., Massetti, M., Lanza, G. A., et al. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.2003704 · Cited by 16
The emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 16
“In combination with dexamethasone, lenalidomide showed response rates of 55 – 60% in patients with relapsed disease [12,13].”
BackgroundBenevolo, G., Larocca, A., Gentile, M., Pregno, P., Gay, F., Botto, B., Frairia, C., Evangelista, A., Morabito, F., Boccadoro, M., et al. (2010) · Cancer · doi:10.1002/cncr.25743 · Cited by 15
Novel immunomodulatory compounds in multiple myeloma
Saini, N. Y., & Mahindra, A. K. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.749235 · Cited by 16
“Two subsequent large, randomized, multicenter, doubleblind, placebo-controlled studies in patients with relapsed or refractory myeloma -- the MM-009 and the MM-010 trial [25,26] -- confirmed the efficacy and tolerability of lenalidomide.”
BackgroundPersona, E. P., Gironella, M., Sánchez, P. J. G., & González, A. P. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0102-x · Cited by 15
(KMMWP), K. M. M. W. P., Kım, K., Kim, S. J., Voelter, V., Suh, C., Yoon, S., Lee, J., Kwak, J., Ryoo, H. M., Kim, Y. S., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1893-z · Cited by 16
“5 %, respectively, for the lenalidomide-treated groups [5, 6].”
BackgroundInfluentialPlesner, T., Arkenau, H., Gay, F., Minnema, M. C., Boccadoro, M., Moreau, P., Cavenagh, J. D., Perrot, A., Laubach, J. P., Krejcik, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15879 · Cited by 15
“(Dimopoulos et al, 2007; Weber et al, 2007).”
Multiple myeloma: the disease and its treatment
Gupta, M., Pal, R. N., & Tikoo, D. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130302 · Cited by 17
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
Donato, F., Gay, F., Bringhen, S., Troia, R., & Palumbo, A. P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.908848 · Cited by 14
“The PR rate seen in this study was superior to that observed in other trials [10,11] that evaluated lenalidomide in combination with high-dose dexamethasone in relapsed/ refractory MM (82 vs 60 and 61%, respectively).”
BackgroundResultThe role of tandem stem cell transplantation for multiple myeloma patients
Martino, M. V., Recchia, A. G., Fedele, R., Neri, S., Vincelli, I. D., Moscato, T., Gentile, M., & Morabito, F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136285 · Cited by 16
Lin, H. M., Davis, K. L., Kaye, J. A., Luptakova, K., Nagar, S. P., & Mohty, M. (2019) · Advances in Hematology · doi:10.1155/2019/4625787 · Cited by 14
Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies
Hughes, J. H., Phelps, M. A., Upton, R. N., Reuter, S. E., Gao, Y., Byrd, J. C., Grever, M. R., Hofmeister, C. C., Marcucci, G., Blum, W. G., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13873 · Cited by 14
Petrucci, M. T., Levi, A., Bringhen, S., Scotti, S., Gentilini, F., Russo, S., Siniscalchi, A., Larocca, A., Grammatico, S., Boccadoro, M., et al. (2012) · Cancer · doi:10.1002/cncr.27820 · Cited by 14
“The median PFS in our study was 18 months, which was longer than that obtained with bortezomib in the ‘‘Assessment of Proteasome Inhibition for Extending Remissions’’ (APEX) study (8 months) or with lenalidomide and dexamethasone (12 months).(26) In our patients, adverse events were manageable and predictable: Thrombo…”
ResultSelf-citationCost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer’s perspective
Kühne, F., Mittendorf, T., Germing, U., Tesch, H., Weinberg, R., Grabenhorst, U., Mohr, A., Lipp, R., & von der Schulenburg, J. M. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1017-y · Cited by 14
Lenalidomide: a synthetic compound with an evolving role in cancer management
Saloura, V., & Grivas, P. D. (2010) · Hematology · doi:10.1179/102453310x12647083620921 · Cited by 16
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
Lacy, M. Q., & Tefferi, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.552139 · Cited by 14
“The corresponding figure for lenalidomide combined with dexamethasone is 55–60% [5,6].”
BackgroundTreatment of relapsed and refractory myeloma
Reece, D. E., Leitch, H. A., Atkins, H. L., Voralia, M., Canning, L. A., LeBlanc, R., Belch, A. R., White, D. J., & Kovacs, M. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802064941 · Cited by 14
“Lenalidomide, a thalidomide analogue with more potent anti-myeloma activity and a more favourable side-effect profile, has been investigated both as a single agent and in combination in the relapsed/refractory setting (Table V) [41,42,113,114].”
BackgroundMethodResultInfluentialManier, S., & Leleu, X. P. (2011) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2011.04.001 · Cited by 32
Püntmann, I., Schmacke, N., Melander, A., Lindberg, G., & Mühlbauer, B. (2010) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-10-5 · Cited by 14
“Two studies were found which met the EVITA requirements [12,13].”
ResultBenson, D. M., Panzner, K., Hamadani, M., Hofmeister, C. C., Bakan, C. E., Smith, M., Elder, P., Krugh, D., O’Donnell, L. C., & Devine, S. M. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903480728 · Cited by 14
Ghobrial, I. M., & Stewart, A. K. (2009) · Hematology · doi:10.1182/asheducation-2009.1.587 · Cited by 14
Ishak, K. J., Caro, J. J., Drayson, M. T., Dimopoulos, M. A., Weber, D., Augustson, B. M., Child, J. A., Knight, R., Iqbal, G., Dunn, J., et al. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.1182 · Cited by 14
Self-citationSuzuki, K., Shinagawa, A., Uchida, T., Taniwaki, M., Hirata, H., Ishizawa, K., Matsue, K., Ogawa, Y., Shimizu, T., Otsuka, M., et al. (2016) · Cancer Science · doi:10.1111/cas.12916 · Cited by 16
Lee, Q., Mocarski, M., & Sun, S. X. (2016) · PubMed Central · Cited by 14
Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre
Zammit, S. C., Sanders, D., & Sidhu, R. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1325929 · Cited by 14
Richardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
“Ixazomib and carfilzomib, an intravenous next-generation proteasome inhibitor approved in RRMM [47,49], are currently being investigated as maintenance therapies with Rd after ASCT in clinical trials (ClinicalTrials.gov identifiers: NCT02406144, NCT02659293, NCT02203643, NCT01816971, and NCT02389517; Table 2).”
BackgroundResultInfluentialSelf-citationRisk assessment of venous thromboembolism in hematological cancer patients: a review
Chan, T. S. Y., Hwang, Y., & Tse, E. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1751608 · Cited by 15
“When lenalidomide is combined with dexamethasone, the risk is increased to 11–15% [46,47].”
BackgroundDiagnosis and the current trends in multiple myeloma therapy
Dmoszyńska, A. (2008) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.490 · Cited by 14
Sekiguchi, Y., Shimada, A., Imai, H., Wakabayashi, M., Sugimoto, K., Nakamura, N., Sawada, T., Komatsu, N., & Noguchi, M. (2014) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-014-0355-7 · Cited by 14
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
Chen, W., Yang, Y., Chen, Y., Du, F., & Zhan, H. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s104195 · Cited by 14
McCarthy, P. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0006 · Cited by 15
Vitovski, S., Chantry, A., Lawson, M. A., & Croucher, P. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035830 · Cited by 13
“More recently, the introduction of new, targeted, therapies such as lenalidomide and bortezomib, has resulted in increased survival, however, even with these new agents patients ultimately relapse [6,7].”
BackgroundWang, T., Ahluwalia, R., Fiala, M. A., Trinkaus, K. M., Cox, D., Jaenicke, M., Moliske, C. C., Carson, K. R., Wildes, T. M., Tomasson, M. H., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.803547 · Cited by 15
Lenalidomide: an update on evidence from clinical trials
Dimopoulos, M. A., & Terpos, E. (2010) · Blood Reviews · doi:10.1016/s0268-960x(10)70005-9 · Cited by 14
“The most common adverse events in the lenalidomide-plusdexamethasone group were neutropenia, thrombocytopenia, and venous thromboembolism.(14) A pooled analysis of data from both the MM-009 and MM-010 studies after a follow-up of 48 months confirmed the improved response rate and survival advantage associated with len…”
BackgroundMethodResultInfluentialSelf-citationSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Weisel, K. C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94531 · Cited by 15
Maintenance and continuous therapy for multiple myeloma
Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13
“The study design of MM-010 was similar to that of MM-009: patients with RRMM received either RD or placebo plus dexamethasone until PD [57].”
MethodSelf-citationTerpos, E., Katodritou, E., Symeonidis, A. S., Zagouri, F., Gerofotis, A., Christopoulou, G., Gavriatopoulou, M., Christoulas, D., Ntanasis‐Stathopoulos, I., Kourakli, A., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32125 · Cited by 14
Self-citationCope, S. F., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M., Weisel, K. C., & Jansen, J. P. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.003 · Cited by 13
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
Chen, L., & Gooding, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038329 · Cited by 16
“Clinical studies in relapsed/refractory MM (RRMM) showed higher response rates on adding dexamethasone to lenalidomide (54), indicating the antiproliferative effect of IMiDs to be more significant than their immunomodulatory effects.”
BackgroundFuture Novel Single Agent and Combination Therapies
Cirstea, D. D., Vallet, S., & Raje, N. S. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181c51c8e · Cited by 14
Thromboembolic risk in hematological malignancies
Franchini, M. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1010 · Cited by 13
Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
Ghani, S., Ustwani, O. A., Khalid, B., Bogner, P. N., Grassi, M. A., Powell, J., & Bhat, S. A. (2013) · PubMed · Cited by 13
Mechanisms of action and resistance for multiple myeloma novel drug treatments
Iida, S. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2040-0 · Cited by 13
Zamagni, E., Petrucci, A., Tosi, P., Tacchetti, P., Perrone, G., Brioli, A., Pantani, L., Zannetti, B. A., Terragna, C., Baccarani, M., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1320-2 · Cited by 13
A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease
Teh, B. W., Khot, A. S., Harrison, S. J., Prince, H. M., & Slavin, M. A. (2013) · Transplant Infectious Disease · doi:10.1111/tid.12106 · Cited by 13
“Patients in lenalidomide treatment trials have had significantly higher rates of myelosuppression, while bortezomib-treated patients have been found to have selective depletion of reactive T cells and blunted cytokine responses (18, 19).”
BackgroundSelf-citationMcCormack, P. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0269-6 · Cited by 13
“Lenalidomide was first registered for use in combination with dexamethasone for the treatment of multiple myeloma in patients who had received at least one prior therapy [6] based on the positive results of two large, randomized, placebo-controlled trials [28, 29], but has since been investigated in different drug com…”
MethodRaje, N. S., Faiman, B. M., Harvey, R. D., Kurtin, S. E., Lonial, S., Kumar, S. K., Cohen, A. D., Conde, M. Á., Giralt, S., Recine, M. S., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.011 · Cited by 13
The use of Novel Agents in Multiple Myeloma Patients with Hepatic Impairment
Stansfield, L., Gonsalves, W. I., & Buadi, F. K. (2015) · Future Oncology · doi:10.2217/fon.14.270 · Cited by 13
Warner, J. L., Alterovitz, G., Bodio, K., & Joyce, R. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001355 · Cited by 13
Morgenroth, A., Dinger, C., Zlatopolskiy, B. D., Al‐Momani, E., Glatting, G., Mottaghy, F. M., & Reske, S. N. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.02.018 · Cited by 13
“Agents such as dexamethasone (Dex), thalidomide, lenalidomide and bortezomib achieve responses in MM patients [1–4].”
BackgroundRögnvaldsson, S., Gasparini, A., Þorsteinsdóttir, S., Sverrisdottir, I. S., Eyþórsson, E. S., Long, T. E., Pálmason, R., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19957 · Cited by 13
Advances in treatment for relapses and refractory multiple myeloma
Richards, T. A., & Weber, D. (2010) · Medical Oncology · doi:10.1007/s12032-009-9407-5 · Cited by 12
Touzeau, C., Blin, N., Clavert, A., Roland, V., Loirat, M., Tessoulin, B., Gouill, S. L., Planche, L., Pennetier, M., Mahé, B., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.654116 · Cited by 12
Myeloma Kidney: Improving Clinical Outcomes?
Haynes, R., Leung, N., Kyle, R. A., & Winearls, C. G. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.03.001 · Cited by 12
Zhou, D.-B., Yu, L., Du, X., Jin, J., Cai, Z., Chen, F., Ke, X., Li, X., Wu, D., Meng, F., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1771-7 · Cited by 13
Genomic stratification of multiple myeloma treated with novel agents
Jiang, A., Reece, D. E., & Chang, H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.608449 · Cited by 14
Sinha, S., Rajkumar, S. V., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Dingli, D., Kyle, R. A., Gertz, M. A., & Kumar, S. K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08023.x · Cited by 12
“Even shorter TTP was seen with Dex in the setting of relapsed myeloma (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundLeleu, X. P., Kyriakou, C. A., Broek, I. V., Murphy, P. T., Bacon, P., Lewis, P., Gilet, H., Arnould, B., & Petrucci, M. T. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.20 · Cited by 12
Preventing osteolytic lesions and osteomyelitis in multiple myeloma
Dao, A., McDonald, M. M., Savage, P. B., Little, D. G., & Schindeler, A. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100460 · Cited by 15
Extramedullary plasmacytomas in the context of multiple myeloma
Aguado, B., Íñigo, B., Sastre, J. L., & Oriol, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0073-6 · Cited by 12
Corso, A., Zappasodi, P., Barbarano, L., Petrucci, M. T., Palumbo, A., Caravita, T., Mangiacavalli, S., Cafro, A. M., Varettoni, M., Gay, F., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.03.015 · Cited by 12
Self-citationNew Immunomodulatory Drugs in Myeloma
Lacy, M. Q. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0077-y · Cited by 12
“In relapsed myeloma, thalidomide with dexamethasone has response rates of 40% to 50% [4], and lenalidomide with dexamethasone has response rates of 55% to 60% [ 5 , 6]. Bortezomib alone has a response rate of 38% in relapsed patients [7].”
BackgroundZago, M., Oehrlein, K., Rendl, C., Hahn‐Ast, C., Kanz, L., & Weisel, K. C. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2149-2 · Cited by 12
Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
Saad, A. A., Sharma, M. R., & Higa, G. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l428 · Cited by 13
Cruz, M. P. (2016) · PubMed · Cited by 20
Maharaj, S. S., Chang, S., Seegobin, K., Serrano-Santiago, I., & Zuberi, L. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1330153 · Cited by 12
“However, in patients treated with combination lenalidomide and high-dose dexamethasone, randomized studies recorded a significant increased risk of VTE [3,4] including deep vein thrombosis, pulmonary embolism, and cerebral venous thrombosis.”
BackgroundResultKorean Multiple Myeloma 151 Investigators, Shin, J., Lee, J., Kım, K., Min, C., Lee, J., Suh, C., Kim, J. S., Lee, Y. J., Yoon, S., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2540-1 · Cited by 12
Li, X., Sun, X., Fang, B., Leng, Y., Sun, F., Wang, Y., Wang, Q., Jin, J., Yang, M., Xu, B., et al. (2022) · Thrombosis Journal · doi:10.1186/s12959-023-00534-y · Cited by 13
“In previous research, it was found that when thalidomide and dexamethasone or lenalidomide and dexamethasone were used in a combined manner, the incidence increased to 17% and that the incidence increased even more to 26–58% in patients who were also given further chemotherapy treatment [25, 31].”
BackgroundNeurotoxicity of Biologically Targeted Agents in Pediatric Cancer Trials
Wells, E. M., Rao, A. A. N., Scafidi, J., & Packer, R. J. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.02.006 · Cited by 12
How best to use new therapies in multiple myeloma
Dingli, D., & Rajkumar, S. V. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.03.001 · Cited by 12
U nited K ingdom M yeloma F orum ( UKMF ) position statement on the use of bendamustine in myeloma
Pratt, G., Bowcock, S. J., Lai, M., Bell, S., Bird, J. M., D’Sa, S., Cavenagh, J. D., Cook, G., Morgan, G. J., Owen, R. G., et al. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12097 · Cited by 12
Mondello, P., Pitini, V. V., Arrigo, C., Mondello, S., Mian, M., & Altavilla, G. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-123 · Cited by 12
Where are we now with the treatment of multiple myeloma?
Morgan, G. J., & Rasche, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.82 · Cited by 12
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 14
Moodad, S., Hajj, R. E., Hleihel, R., El‐Hajjar, L., Tawil, N., Karam, M., Hamie, M., Merhi, R. A., El-Sabban, M. E., & Hajj, H. E. (2020) · Cancers · doi:10.3390/cancers12092483 · Cited by 12
“Lenalidomide (Lena) is an immunomodulatory agent and a thalidomide analogue approved for the treatment of multiple myeloma patients [42,43].”
BackgroundMajor Advances in the Treatment of Cancer What does a Non-Oncologist need to know?
Burney, I. A., & Al-Moundhri, M. S. (2008) · Sultan Qaboos University medical journal · doi:10.18295/2075-0528.2710 · Cited by 12
The Potential of Immunomodulatory Drugs in the Treatment of Solid Tumors
Dalgleish, A. G., & Galustian, C. (2010) · Future Oncology · doi:10.2217/fon.10.105 · Cited by 12
“However, the response rates increase markedly when lenalidomide (25 mg on days 1–21 of a 28-day cycle) is combined with dexamethasone [6,7].”
BackgroundTargeted therapy of multiple myeloma
Kyle, R. A. (2012) · Hematology · doi:10.1179/102453312x13336169156339 · Cited by 14
Incorporating Monoclonal Antibodies Into the Therapy of Multiple Myeloma
Bladé, J., de Larrea, C. F., & Rosiñol, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4178 · Cited by 12
Nadeem, O., Ailawadhi, S., Khouri, J., Williams, L. S., Catamero, D., Maples, K. T., & Berdeja, J. G. (2024) · Cancers · doi:10.3390/cancers16051023 · Cited by 13
“…an increased risk of second primary malignancies (SPMs; particularly hematological malignancies), rash, diarrhea, constipation, hematological toxicities such as neutropenia and thrombocytopenia, myocardial infarction, venous thromboembolism (VTE), arterial thromboembolism, and stroke [3,11–13].”
BackgroundRichardson, P. G. G., Laubach, J. P., Schlossman, R. L., Ghobrial, I. M., Redman, K., McKenney, M., Warren, D. L., Noonan, K., Lunde, L. E., Doss, D. S., et al. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01765.x · Cited by 11
Shah, N. D., & Lonial, S. (2010) · Hematology · doi:10.1182/asheducation-2010.1.310 · Cited by 13
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.